Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1

The RV144 HIV vaccine trial included a recombinant HIV glycoprotein 120 (gp120) construct fused to a small portion of herpes simplex virus 1 (HSV-1) glycoprotein D (gD) so that the first 40 amino acids of gp120 were replaced by the signal sequence and the first 27 amino acids of the mature form of g...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Virol
Hlavní autoři: Wang, Kening, Tomaras, Georgia D., Jegaskanda, Sinthujan, Moody, M. Anthony, Liao, Hua-Xin, Goodman, Kyle N., Berman, Phillip W., Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Nitayapan, Sorachai, Kaewkungwal, Jaranit, Haynes, Barton F., Cohen, Jeffrey I.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2017
Témata:
Vaccines and Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5599770/
https://ncbi.nlm.nih.gov/pubmed/28701403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00411-17
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky